Jacob P. Van Vloten
Guelph, ON N1G2W1, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 14, 2025
Investigating the effect of reduced temperatures on the efficacy of rhabdovirus-based viral vector platforms.
Journal: The Journal of general virology
Published: August 22, 2024
Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy.
Journal: Research square
Published: December 04, 2023
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.
Journal: Nature communications
Published: November 07, 2023
Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer.
Journal: Frontiers in microbiology
Published: October 21, 2023
A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 17, 2023
Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancer.
Journal: Molecular therapy oncolytics
Published: December 30, 2022
Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies.
Journal: Frontiers in immunology
Published: September 06, 2022
The Role of Neutrophils in Oncolytic Orf Virus-Mediated Cancer Immunotherapy.
Journal: Cells
Published: August 03, 2022
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.
Journal: Science translational medicine
Published: April 13, 2022
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer.
Journal: Journal for immunotherapy of cancer
Published: February 12, 2022
AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma.
Journal: Biomedicines
Published: December 05, 2021
Last Updated: 09/26/2026